Abstract 443TiP
Background
Osteosarcoma is a bone malignancy that occurs primarily in adolescents and young adults. Approximately 30% of patients (pts) with localized disease and 80% of pts with metastatic disease at diagnosis will relapse. Lenvatinib (LEN) is a multikinase inhibitor that directly inhibits tumor growth, and may increase the uptake of chemotherapy into tumor tissue by inhibiting angiogenesis. In a phase I/II study (E7080-G000-207; ITCC-050), LEN (14 mg/m2 dose) + ifosfamide (I) + etoposide (E) demonstrated a PFS rate at 4 months (PFS-4m) of 80% (95% CI: 61–91), with a manageable safety profile in pts with relapsed/refractory osteosarcoma (Gaspar ESMO 2019). This study aims to confirm the activity of LEN + I and E that was observed in the completed phase I/II study.
Trial design
This study will evaluate LEN in combination with I and E in pts (proposed N=72, with randomization of at least 32 pts < 18 yrs old) aged 2 to 25 yrs with confirmed diagnosis of osteosarcoma that is refractory or relapsed following 1-2 prior systemic treatments. Pts previously treated with I and E are eligible, except those with a history of I-related grade ≥ 3 nephrotoxicity or encephalopathy. Randomization will be stratified by time to first relapse/refractory disease (< 18 or ≥ 18 mos) and by age (< 18 or ≥ 18 yrs). Pts in arm A will receive daily oral LEN 14 mg/m2 + I 3000 mg/m2/day (IV, Days 1-3 of each cycle for ≤5 cycles) and E 100 mg/m2/day (IV, Days 1-3 of each cycle for ≤5 cycles). Pts in arm B will receive I 3000 mg/m2/day (IV, Days 1-3 of each cycle for ≤5 cycles) and E 100 mg/m2/day (IV, Days 1-3 of each cycle for ≤5 cycles). Treatment will occur in 21-day cycles. The primary objective is PFS-4m by independent imaging review (IIR) using RECIST 1.1 (% of pts alive without progressive disease at week 18). Secondary objectives include PFS, OS, ORR, safety and tolerability, LEN pharmacokinetics characterization in pts in arm A, and quality of life. Tumor assessments will be performed by the investigator every 6 wks. Disease progression must be confirmed by IIR. All AEs will be recorded.
Clinical trial identification
NCT04154189.
Legal entity responsible for the study
Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Funding
Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Disclosure
N. Gaspar: Advisory/Consultancy, Travel/Accommodation/Expenses: Eisai; Advisory/Consultancy: Ipsen. Q. Campbell-Hewson: Travel/Accommodation/Expenses: Eisai. S.S. Bielack: Advisory/Consultancy, Research grant/Funding (institution): Bayer; Advisory/Consultancy: Lilly; Advisory/Consultancy: Sensorion; Advisory/Consultancy: Ipsen; Advisory/Consultancy: Roche; Advisory/Consultancy: Boehringer Ingelheim; Research grant/Funding (institution): Eisai; Research grant/Funding (institution): Loxo. F. Bautista: Honoraria (self), Advisory/Consultancy: Amgen; Honoraria (self), Travel/Accommodation/Expenses: Jazz Pharmaceuticals; Advisory/Consultancy: Bayer; Advisory/Consultancy, Travel/Accommodation/Expenses: EUSA Pharma; Travel/Accommodation/Expenses: Takeda. C. Meazza: Speaker Bureau/Expert testimony: Takeda. K. Janeway: Advisory/Consultancy, Travel/Accommodation/Expenses: Bayer; Research grant/Funding (institution): Amgen. D.A. Morgenstern: Advisory/Consultancy: Boehringer-Ingelheim; Advisory/Consultancy: Roche; Advisory/Consultancy: Bayer; Research grant/Funding (institution): Bristol-Myers Squibb; Travel/Accommodation/Expenses: EUSA Pharma. L. Dutta, J. McKenzie, K. O'Hara, J. Huang, C.E. Okpara: Full/Part-time employment: Eisai. B. Bidadi: Full/Part-time employment: Merck & Co. Inc.; Shareholder/Stockholder/Stock options: Merck. All other authors have declared no conflicts of interest.
Resources from the same session
62P - IGF axis in breast cancer recurrence and metastasis
Presenter: Hajara Akhter
Session: e-Poster Display Session
63P - Butterfly pea (<italic>Clitoria ternatea</italic> Linn.) flower extract prevents MCF-7 HER2-positive breast cancer cell metastasis in-vitro
Presenter: Azzahra Asysyifa
Session: e-Poster Display Session
64P - Pre-treatment absolute white blood cell profile count as metastatic predictive factors in invasive ductal carcinoma breast cancer
Presenter: Wikania I Gede
Session: e-Poster Display Session
65P - The new mouse anti-nNav1.5 monoclonal antibody
Presenter: Nur Aishah Sharudin
Session: e-Poster Display Session
66P - The TILs near solid structures is a potential prognostic factor of distant metastases in the luminal HER2-negative breast cancer
Presenter: Vladimir Alifanov
Session: e-Poster Display Session
73P - Selinexor in combination with carboplatin and pemetrexed (CP) in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multi-arm phase Ib study
Presenter: Kyaw Thein
Session: e-Poster Display Session
74P - Comprehensive transcriptome analysis of endoplasmic reticulum stress in osteosarcomas
Presenter: Yoshiyuki Suehara
Session: e-Poster Display Session
75P - The evaluation of selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer
Presenter: Leo Yamada
Session: e-Poster Display Session
76P - Targeted tumour photoImmunotherapy against triple-negative breast cancer therapy
Presenter: Vivek Raju
Session: e-Poster Display Session
77P - Dual targeting oxidative phosphorylation and glycolysis in triple-negative breast cancers: En route to effective inhibition of tumour metabolism
Presenter: Alexander Scherbakov
Session: e-Poster Display Session